Specific Plasma Autoantibody Reactivity in Myelodysplastic Syndromes

[1]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[2]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[3]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[4]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[5]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[6]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[7]  P. Greenberg.  Molecular and genetic features of myelodysplastic syndromes , 2012, International journal of laboratory hematology.

[8]  G. Pietersz,et al.  Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond , 2012, Nature Reviews Drug Discovery.

[9]  Hugo Y. K. Lam,et al.  Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.

[10]  P. Font,et al.  Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification , 2012, Annals of Hematology.

[11]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[12]  Michael N. Alonso,et al.  B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies , 2011, Nature Medicine.

[13]  Cahir J. O'Kane,et al.  Lysosomal positioning coordinates cellular nutrient responses , 2011, Nature Cell Biology.

[14]  P. Greenberg.  Current therapeutic approaches for patients with myelodysplastic syndromes , 2010, British journal of haematology.

[15]  M Cazzola,et al.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.

[16]  Wei Zhang,et al.  Protein microarray: sensitive and effective immunodetection for drug residues , 2010, BMC biotechnology.

[17]  Robert Tibshirani,et al.  Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. , 2009, Blood.

[18]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[19]  G. Mufti,et al.  IL‐17‐producing CD4+ T cells, pro‐inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome , 2009, British journal of haematology.

[20]  G. Mills,et al.  A novel AKT3 mutation in melanoma tumours and cell lines , 2008, British Journal of Cancer.

[21]  M. Manns,et al.  Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease , 2008, Proceedings of the National Academy of Sciences.

[22]  Gil Mor,et al.  Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays , 2007, Proceedings of the National Academy of Sciences.

[23]  Tarn Duong,et al.  ks: Kernel Density Estimation and Kernel Discriminant Analysis for Multivariate Data in R , 2007 .

[24]  G. Mufti,et al.  CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). , 2007, Blood.

[25]  R. Pearson,et al.  A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. , 2006, Cancer research.

[26]  Mark Gerstein,et al.  ProCAT: a data analysis approach for protein microarrays , 2006, Genome Biology.

[27]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[28]  Shaohui Hu,et al.  Severe acute respiratory syndrome diagnostics using a coronavirus protein microarray. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Marisavljević,et al.  Immunologic abnormalities in myelodysplastic syndromes , 2006, Medical oncology.

[30]  T. Niewold,et al.  Acute phase reaction and acute phase proteins. , 2005, Journal of Zhejiang University. Science. B.

[31]  Debashis Ghosh,et al.  Autoantibody signatures in prostate cancer. , 2005, The New England journal of medicine.

[32]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[33]  P. Pavlidis.  Using ANOVA for gene selection from microarray studies of the nervous system. , 2003, Methods.

[34]  Shaogang Gong,et al.  Recognising trajectories of facial identities using kernel discriminant analysis , 2003, Image Vis. Comput..

[35]  T. Tauchi,et al.  Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[37]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[38]  G. Mufti,et al.  The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. , 2000, Blood.

[39]  G. Baudat,et al.  Generalized Discriminant Analysis Using a Kernel Approach , 2000, Neural Computation.

[40]  B. Scholkopf,et al.  Fisher discriminant analysis with kernels , 1999, Neural Networks for Signal Processing IX: Proceedings of the 1999 IEEE Signal Processing Society Workshop (Cat. No.98TH8468).

[41]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[42]  J. R. Koehler,et al.  Modern Applied Statistics with S-Plus. , 1996 .

[43]  G. Palomaki,et al.  Reference distributions for the negative acute‐phase serum proteins, albumin, transferrin and transthyretin: A practical, simple and clinically relevant approach in a large cohort , 1999, Journal of clinical laboratory analysis.

[44]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[45]  P. Greenberg,et al.  Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. , 1996, Blood.

[46]  H. Preisler,et al.  Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis , 1995, American journal of hematology.

[47]  K. Ohyashiki,et al.  Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. , 1994, Cancer research.

[48]  K. Richert-Boe,et al.  In vitro hematopoiesis in myelodysplasia: liquid and soft-gel culture studies. , 1992, Hematology/oncology clinics of North America.

[49]  D. Cox,et al.  An Analysis of Transformations , 1964 .